risedronate sodium
HMR4003B_4034
Approved small_molecule completed
Quick answer
risedronate sodium for Osteoporosis, Postmenopausal is a Approved program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pasteur
- Indication
- Osteoporosis, Postmenopausal
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed